Guggenheim Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Guggenheim Capital’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-72,367	Closed	-$1.27M	–	2293
2021 Q3	$1.27M	Buy	72,367 +18,715	+35%	+$219K	0.01%	1296
2021 Q2	$520K	Buy	53,652 +2,455	+5%	+$23.1K	﹤0.01%	1810
2021 Q1	$550K	Buy	51,197 +24,415	+91%	+$302K	﹤0.01%	1671
2020 Q4	$394K	Buy	+26,782	New	+$386K	﹤0.01%	1736

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Guggenheim Capital's TRIL Position: Q4 2021 in Review

Guggenheim Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 72,367 shares — an estimated $1.27M sold.

Guggenheim Capital first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $1.27M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Guggenheim Capital reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Guggenheim Capital sold 72,367 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.27M.
Guggenheim Capital first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Guggenheim Capital's Trillium Therapeutics Inc. position peaked at $1.27M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Guggenheim Capital's 13F filing for Q4 2021, filed 14 Feb 2022.